tirasemtiv

Small moleculeexperimental

Clinical trial activity

8 trials · 5 clinical orgs · 0 marketing orgs

Phase 1
0
Phase 2
8
Phase 3
2
Phase 4
0

Earliest trial started Mar 1, 2010 (NCT01089010)

Timeline

2010s

  1. Jan 1, 2010

    Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 2015

    Earliest Phase 3 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

C#Cc1cnc2nc(O)n(C(CC)CC)c2n1
Mol. weight
230.27 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • ck-2017357
  • ck-2017357
  • ck-2017357
  • ck-2017357
  • tirasemtiv
  • tirasemtiv
  • tirasemtiv
  • tirasemtiv
  • tirasemtiv

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT02936635Phase 3Oct 1, 2016Cytokinetics
NCT02496767Phase 3Aug 1, 2015Cytokinetics
NCT01709149Phase 2Oct 1, 2012Cytokinetics, State University of New York, Syracuse
NCT01486849Phase 2Nov 1, 2011Cytokinetics, State University of New York, Syracuse
NCT01378676Phase 2Jun 1, 2011Cytokinetics, State University of New York, Syracuse
NCT01268280Phase 2Dec 1, 2010Cytokinetics, National Institute of Neurological Disorders and Stroke (NINDS)
NCT01131013Phase 2May 1, 2010Colorado Prevention Center, Cytokinetics, University of Minnesota
NCT01089010Phase 2Mar 1, 2010Cytokinetics, State University of New York, Syracuse
Showing 8 of 8 trials
Page 1 / 1

Organizations

Research & Development (5)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
CytokineticsFor profit8822010
State University of New York, SyracuseAcademic/Hospital4012010
Colorado Prevention CenterAcademic/Hospital1012010
National Institute of Neurological Disorders and Stroke (NINDS)Government1012010
University of MinnesotaAcademic/Hospital1012010
5 organizations
Page 1 / 1